TSTakashi Sone

Takashi Sone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takashi Sone has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations

    by Hayato Koba, Hideharu Kimura, Shingo Nishikawa, Takashi Sone, Miki Abo, Johsuke Hara, Kazuyoshi Hosomichi, Atsushi Tajima, Kazuo Kasahara


  • A Case of Pleomorphic Carcinoma of the Lung with Gingival and Gastroduodenal Metastases That Resulted in Small-intestinal Perforation

    by Taro Yoneda, Hideharu Kimura, Hayato Koba, Shingo Nishikawa, Takashi Sone, Kazuo Kasahara

    背景.肺多形癌の予後は不良とされる.外科的手術が可能であった症例に関しては,リンパ節転移を認めなかった症例は長期予後が期待できるとの報告も存在するが,化学療法に関して標準的なレジメンは確立されていない.症例.59歳.男性.2015年夏から背部痛,血痰が出現し精査加療目的に当科に紹介となった.精査にて肺多形癌cT2bN2M1b(ADR)stage IVと診断された.全身化学療法としてカルボプラチン・パクリタキセル併用療法を3サイクル施行した.右副腎転移増大,多発肝転移,胃・十二指腸転移,歯肉転移を認め,高度貧血を伴っていた.2次治療としてニボルマブを投与した.2サイクル施行するも肝転移病変の増悪を認めた.その後,小腸転移による小腸穿孔を発症し緊急手術となった.結論.本症例は歯肉,胃,十二指腸転移,小腸転移など消化器系の多臓器に転移をきたした肺多形癌であった.本症例では免疫チェックポイント阻害薬の効果は得られなかった.

  • Correlation between EGFR mutation T790M predominancy in initial biopsy detected by droplet digital PCR and acquired resistant mechanism to EGFR TKI.

    by Hayato Koba, Taro Yoneda, Shingo Nishikawa, Takashi Sone, Hideharu Kimura, Kazuo Kasahara

    E20602 Background: The EGFR T790M mutation is the most common mechanism about drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in EGFR-mutated lung cancer. The third generation EGFR TKI has been reported a good efficacy to the patient who has a non small cell lung cancer harvouring the EGFR T790M mutation. On the other hand, several highly sensitive assays can already detect this mutation in pretreatment tissue biopsy. This study aim to evaluate a correlation the EGFR T790M mutation dominancy about the EGFR-mutated lung cancer which was not until exposed EGFR TKI therapy and actual resistance mechanism. Methods: We assessed the 26 EGFR TKI-free samples from EGFR-mutated non-small cell lung cancer by droplet digital PCR (ddPCR). T790M mutation dominancy ratio was calculated from isolated two PCR data about common mutation and T790M mutation and was estimated according to the following various clinical characteristics, that is actual T790M mutation using standard clinical method, age, sex, smoking status, PFS and treatment response of EGFR-TKIs. Results: We can detect the T790M mutation in 19 cases (73%) in initial biopsy tissue by ddPCR. The mean value of T790M mutation dominancy ratio was 0.48% (0.00-69.09%) and it is not difference in this ratio between T790M-positive and –negative cases, using standard clinical method (p = 0.92). The other clinical characteristics were not related with T790M mutation dominancy at all. Conclusions: T790M mutation was detected in most of the EGFR TKI-free sample, however the T790M mutation dominancy in pretreatment may not be related to actual post-treatment resistant mechanism whether EGFR T790M mutation was found.

  • Open Access

    Squamous cell histological transformation beyond EGFR TKI treatment against EGFR-mutant lung adenocarcinoma

    by Hayato Koba, Shingo Nishikawa, Taro Yoneda, Takashi Sone, Hideharu Kimura, Kazuo Kasahara

  • Two Cases of Small Cell Lung Cancer with Metastasis to the Stomach at Initial Diagnosis

    by Akihito Okazaki, Tomoyuki Araya, Asao Sakai, Takashi Sone, Kazuo Kasahara, Masaki Fujimura

    背景.肺癌の初回診断時に胃転移が確認されることは稀である.症例1.74歳,女性.胸部単純X線で左上葉無気肺を認め,気管支鏡で,左上幹を完全に閉塞する腫瘍性病変からの生検にて,小細胞肺癌と診断した.食欲不振の精査目的の胃内視鏡検査で胃前庭部に中心陥凹を伴う隆起性病変を認め,生検にて免疫染色で肺と同一の小細胞癌を認めたため,胃転移と診断した.カルボプラチン+エトポシド併用療法による全身化学療法を行うも無効で,3か月後に死亡した.症例2.76歳,男性.右下葉原発の小細胞肺癌の治療開始前に心窩部痛があり,胃内視鏡検査で胃体部に中心陥凹を伴う隆起性病変を認め,生検により小細胞肺癌の胃転移と診断した.原疾患の増悪により1か月後に死亡した.結語.食欲不振や心窩部痛のような消化器症状は化学療法の副作用と捉えられがちだが,初回診断時でも,有症状時には上部消化管の評価のため胃内視鏡検査を行うことは有用と考えられた.


  • Open Access

    P2-312: A retrospective study of salvage chemotherapy for advanced non-small cell lung cancer; the efficacy of third and fourth chemotherapy.

    by Yuichi Tambo, Kazuo Kasahara, Hideharu Kimura, Takashi Sone, Tomoyuki Araya, Shunichi Tamori, Masaki Fujimura, Shinji Nakao


    • 1 February 2007
      • Vol. 34  (2) , 217-9

    [A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].

    by Yuichi Tambo, Kazuo Kasahara, Masaki Fujimura, Shunichi Tamori, Tomoyuki Araya, Takashi Sone, Shinji Nakao

    A 56-year-old Japanese man who was suffering from dry cough and right neck mass visited our hospital. Chest X-ray revealed a lung mass shadow in the lower left lung field. We diagnosed it as an advanced large cell carcinoma after conducting transbronchial lung biopsy and neck lymphnode biopsy. A right neck mass enlarged after three chemotherapy regimens of carboplatin and vinorelbine for first-line, docetaxel for second-line, and TS-1 and cisplatin for third-line. Finally, cisplatin (80 mg/m(2), day 1) and gemcitabine (800 mg/m(2), day 1, 8) were administered as fourth-line therapy. Partial response was observed after completing four chemotherapy cycles. In this case, the fourth-line chemotherapy, consisting of cisplatin and gemcitabine, proved effective for refractory NSCLC. Further research should be conducted regarding third-line chemotherapy for NSCLC patients with good performance status.

    • 11 November 2006
      • Vol. 26, 3723-8

    A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer.

    by Kazuo Kasahara, Hideharu Kimura, Kazuhiko Shibata, Tomoyuki Araya, Takashi Sone, Shiho Furusho, Toshiyuki Kita, Hiroki Shirasaki, Yoshitaka Oribe, Yuzo Yoshimi, et al.

    The aim of this phase II study was to evaluate the efficacy of combination chemotherapy consisting of docetaxel and carboplatin in patients with inoperable non-small cell lung cancer (NSCLC). For this multicenter phase II study, the eligibility criteria included histologically or cytologically proven inoperable NSCLC, measurable lesions, Eastern Cooperative Oncology Group performance status (PS) 0-2, adequate organ and bone marrow functions, and written informed consent. Patients received 60 mg/m2 of docetaxel and carboplatin (target AUC 5.5) on day 1 every 3 weeks until disease progression. The primary end-point of this study was response rate and the secondary end-points were toxicities, time to progression and overall survival. A total of 40 patients were enrolled and 39 patients were eligible. A complete response and partial response were observed in 1 and 13 patients, respectively. An objective response rate was 35.9% (95% confidential interval [CI] 20.8-51.0%). The median time to progression was 5.2 months and the median overall survival was 12.0 months. The 1- and 2-year survival rates were 53.8% and 25.1%, respectively. The major toxicities were leukocytopenia and neutropenia. Grade 3 or 4 thrombocytopenia was rare and non-hematological toxicities were generally mild. Grade 3 non-hematological toxicities were observed in 6 patients (2 with nausea and vomiting, 1 with diarrhea, 1 with elevated transaminase levels, 1 with allergic reaction and 1 with edema). No grade 4 non-hematological toxicities were observed. Docetaxel and carboplatin combination chemotherapy was well tolerated and active in Japanese patients with advanced or metastatic NSCLC.


  • Open Access

    A Case of Small Cell Lung Cancer with Cancer-Associated Retinopathy

    by Tomoyuki Araya, Kazuo Kasahara, Masaki Fujimura, Takashi Sone, Akihiro Yoshimoto, Shinji Nakao

    背景.悪性腫瘍随伴網膜症(cancer-associated retinopathy:CAR)は腫瘍随伴神経症の一つで上皮由来の悪性腫瘍,特に肺小細胞癌への合併が多く報告されている.我々は肺小細胞癌に合併し,血清抗recoverin抗体は陰性であったが,腫瘍組織においてrecoverin抗原を証明した稀なCARの1例を経験した.症例.77歳,男性.2003年6月より視力障害を認め,網膜電図による網膜電位の低下と,多局所網膜機能解析による網膜全般にわたる著しい電位低下を認めたため,CARが疑われた.全身検索によって右肺下葉の腫瘤影と縦隔リンパ節腫脹が認められ,縦隔リンパ節生検により限局期小細胞肺癌と診断された.血清抗recoverin抗体は陰性であったが,縦隔リンパ節腫瘍組織の免疫染色によってrecoverin抗原が証明された.その後,carboplatin+etoposideによる化学療法および遂時胸部照射を施行し,完全寛解を得たが,視力の改善は認めなかった.結論.CARが疑われ,血清抗recoverin抗体が陰性の場合には,肺癌組織の免疫組織化学的検討によるrecoverin抗原の証明がCAR診断の一助となると考えられた.


  • Open Access

    Changes in Angiogenic Growth Factor Levels After Gefitinib Treatment in Non-small Cell Lung Cancer

    by Akihiro Yoshimoto, Kazuo Kasahara, Makoto Nishio, Takeshi Hourai, Takashi Sone, Hideharu Kimura, Masaki Fujimura, Shinji Nakao

    Background: To investigate the changes in angiogenic growth factor expression before and after gefitinib treatment, and the association between this expression and response to gefitinib treatment, we measured circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), matrix metalloproteinase (MMP) -2 and -9, and tissue inhibitors of metalloproteinase (TIMP) -1 and -2 in patients with non-small cell lung cancer (NSCLC). Methods: Serum and plasma samples were collected from 52 patients before and after gefitinib treatment. The levels of VEGF, bFGF, MMP-2, MMP-9, TIMP-1 and TIMP-2 were measured using a sandwich enzyme immunoassay kit. Results: Of the 52 patients, 17 (32.7%) achieved a partial response, 19 (36.5%) had stable disease and 16 (30.8%) had progressive disease. The levels of VEGF, bFGF, MMP-2, MMP-9, TIMP-1 and TIMP-2 did not change significantly after gefitinib treatment, even in responders. The levels of VEGF in volunteers, responders and non-responders were 384 ± 86.4, 404 ± 94.3 and 719 ± 99.8 pg/ml, respectively. The difference between volunteers and responders was not significant (P = 0.540), while the differences between volunteers and non-responders (P = 0.031), and responders and non-responders (P = 0.028) were significant. Conclusions: Although our results indicate that gefitinib treatment does not affect circulating levels of angiogenic growth factors even in patients who showed a response to gefitinib treatment, low levels of VEGF may predict response to gefitinib treatment in patients with NSCLC.